IPHA Lacutamab: $540M Sobi Deal Funds Phase 3

Innate Pharma (IPHA) has entered a strategic partnership with Swedish Orphan Biovitrum (Sobi) to advance lacutamab, a first-in-class anti-KIR3DL2 antibody, toward an accelerated approval filing in Sézary syndrome, a rare and aggressive subtype of cutaneous T-cell lymphoma. Sobi will pay $75 million upfront and up to $465 million in milestone payments for exclusive global commercialization rights. The deal enables initiation of the TELLOMAK-3 confirmatory Phase 3 study. IPHA shares closed at $1.73 on August 8 on thin ADR volume of just over 5,000 shares.

Lacutamab targets KIR3DL2, a killer immunoglobulin-like receptor expressed on malignant CD4+ T-cells in Sézary syndrome and mycosis fungoides. No therapy specifically targeting KIR3DL2 is approved. Sézary syndrome has roughly 3,000 patients in the US with a median survival under five years. Current options, including bexarotene, interferon, and extracorporeal photopheresis, are palliative and poorly tolerated.

Existing approved therapies for CTCL include mogamulizumab (anti-CCR4) and brentuximab vedotin for CD30-positive subtypes, but neither targets KIR3DL2 or was designed specifically for Sézary syndrome. Lacutamab’s mechanism addresses a different biology: it binds to KIR3DL2 and triggers antibody-dependent cell-mediated cytotoxicity, selectively depleting malignant T-cells while sparing normal immune function.

The deal structure reflects both the opportunity and the binary risk. The $75 million upfront is modest by oncology licensing standards, and the $465 million in milestone payments ties most of the deal value to clinical and regulatory success. Sobi can assume full global development rights after positive Phase 3 results, giving it an option to build a hematology-oncology franchise around lacutamab without committing to the full development cost upfront.

For Innate, the deal provides non-dilutive funding as access to capital tightens across biotech, and at a $1.73 stock price, the $75 million upfront represents meaningful operational runway without shareholder dilution. The company also announced the appointment of Dr. Arvind Sood as Chief Medical Officer on the same day, signaling an operational ramp-up ahead of TELLOMAK-3. Innate’s broader pipeline includes monalizumab (anti-NKG2A) in Phase 3 with AstraZeneca for non-small cell lung cancer and IPH4502, a Nectin-4 antibody-drug conjugate in early solid tumor development.

The risk: TELLOMAK-3 has not started, so any accelerated approval filing and revenue are years away. Sézary syndrome is a small market, and Sobi’s commercial infrastructure is built on rare hematology and immunology rather than oncology. The partnership validates KIR3DL2 biology but does not guarantee it works in a registrational trial. For more on evaluating clinical-stage biotechs, see the guide to reading clinical trial press releases.

Source: Sobi and Innate Pharma partnership announcement, August 10, 2026 · TELLOMAK Phase 2 on ClinicalTrials.gov (NCT03902184)

What It Means for the Trade

Deal honesty: $75 million upfront against $465 million in milestones means Sobi bought an option, and Innate sold a funding event, not an asset at full value. For IPHA at $1.73 with thin ADR volume of barely 5,000 shares, the transaction matters most as non-dilutive runway — the $75 million keeps the TELLOMAK-3 Phase 3 funded and the broader pipeline alive without issuing shares at a price the company would rather forget. The trade reality is that IPHA ADRs are nearly untradeable at that volume; the thesis plays out in Paris, and the ADR just tracks it badly.

For Sobi, the structure is a sensible rare-disease build: assume full development rights after positive Phase 3 data, and pay mostly for success. Sobi’s commercial infrastructure is hematology and immunology — the equipment that sells to the same centers treating CTCL — so the channel fit is genuine even if oncology is not its home turf.

Mechanism and Market Context

KIR3DL2 targeting is a clean biologic story: the receptor is expressed on malignant CD4+ T-cells in Sézary syndrome and mycosis fungoides, so an antibody-drug conjugate approach that triggers antibody-dependent cell-mediated cytotoxicity depletes the malignant clone while sparing normal immune function. The competitive gap is real — mogamulizumab targets CCR4, brentuximab vedotin covers CD30-positive subtypes, and neither was designed for Sézary specifically. In a disease of roughly 3,000 US patients with median survival under five years and palliative-only alternatives, a first-in-class targeted agent has premium orphan pricing power if the data holds.

The TELLOMAK Phase 2 dataset in Sézary showed the signals that justified this deal, but the accelerated-approval filing rests on a confirmatory Phase 3 that has not started. That is the structure to keep in view: the deal announcement funds the trial that decides everything, and the trial reads out years from now.

Risks and What Could Go Wrong

1. Binary, long-dated trial risk. TELLOMAK-3 has not enrolled a patient; CTCL trials are slow-recruiting, and an accelerated approval filing is a 2028-plus event in a best case.
2. Small-market ceiling. Even with premium pricing, 3,000 US Sézary patients caps lacutamab’s revenue potential — this is a franchise satellite, never a pillar.
3. Sobi’s optionality. If the Phase 3 disappoints, Sobi walks having spent $75 million; Innate keeps the program and the problem.
4. Innate’s concentration. The broader pipeline leans on monalizumab with AstraZeneca (where Innate is the junior partner) and an early Nectin-4 ADC — lacutamab is the asset Innate controls, which is exactly why this deal’s milestones matter.

A fine deal for both sides and no reason to buy either stock this week. Watch TELLOMAK-3 enrollment pace as the first evidence it is real.